Pharmaceutical

Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug

Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

Mar 25, 2025 - 06:00
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug
Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.
Read the original article

Tags:

Previous Article

J&J boosts US operations with $55bn investment

Next Article

Revolutionary Nuclear Battery Promises Lifetime Power with Enhanced Safety

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Congress could stop free public access to government-funded research

Opinion: Congress could stop free public access to gove...

Sep 28, 2023

STAT+: FDA approves new treatment from Biogen for rare form of ALS

STAT+: FDA approves new treatment from Biogen for rare ...

Apr 25, 2023

STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’

STAT+: Pharmalittle: Roche buys Roivant bowel disease d...

Oct 24, 2023